Literature DB >> 1375135

Radiotherapy in the treatment of middle ear and mastoid carcinoma.

A R Birzgalis1, A O Keith, W T Farrington.   

Abstract

The treatment of temporal bone carcinoma is a widely discussed topic with marked variation in published results. Most conclude that a combination of radical surgery and radiotherapy is the optimum treatment. The present study reviews the results of radiotherapy used as the main primary treatment for this condition. Five-year survival in 56 patients was 32% for radical and palliative therapy, with an excellent response in 'early' cases. It is concluded that improvement in survival could be attained by defining those groups which would benefit from a combination of treatment methods.

Entities:  

Mesh:

Year:  1992        PMID: 1375135     DOI: 10.1111/j.1365-2273.1992.tb01055.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  5 in total

1.  Treatment and outcome of middle ear cancer.

Authors:  Xianhao Jia; Qin Liang; Fanglu Chi
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10       Impact factor: 2.503

2.  Squamous cell carcinoma of the mastoid - a report of two cases.

Authors:  Oa Lasisi; Ao Ogunleye; Eeu Akang
Journal:  Ghana Med J       Date:  2005-03

3.  Malignant tumors of the ear and temporal bone: a study of 27 patients and review of their management.

Authors:  Pablo Martinez-Devesa; Martyn L Barnes; Chris A Milford
Journal:  Skull Base       Date:  2008-01

4.  Squamous cell carcinoma of the external auditory canal and middle ear results of treatment with subtotal temporal bone resection and postoperative radiotherapy.

Authors:  Rammohan Tiwari; Jolijn Brouwer; Jasper Quak; Hilde Tobi; Henry Winters; Dinesh Mehta
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2002-07

5.  Radiological Findings of Malignant Tumors of External Auditory Canal: A Cross-Sectional Study Between Squamous Cell Carcinoma and Adenocarcinoma.

Authors:  Shuang Xia; Shuo Yan; Mengjie Zhang; Yan Cheng; Jacinth Noel; Vincent Chong; Wen Shen
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.